免疫检查点抑制剂治疗胶质母细胞瘤的成功实施面临的挑战。
Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
机构信息
Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.
Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston Salem, NC 27157, USA.
出版信息
Int J Mol Sci. 2020 Apr 16;21(8):2759. doi: 10.3390/ijms21082759.
Abstract
Glioblastoma (GBM) is the most common and aggressive malignant glioma, treatment of which has not improved significantly in many years. This is due to the unique challenges that GBM tumors present when designing and implementing therapies. Recently, immunotherapy in the form of immune checkpoint inhibition (ICI) has revolutionized the treatment of various malignancies. The application of immune checkpoint inhibition in GBM treatment has shown promising preclinical results. Unfortunately, this has met with little to no success in the clinic thus far. In this review, we will discuss the challenges presented by GBM tumors that likely limit the effect of ICI and discuss the approaches being tested to overcome these challenges.
摘要
胶质母细胞瘤（GBM）是最常见和侵袭性最强的恶性胶质瘤，多年来其治疗并未显著改善。这是由于在设计和实施治疗方案时，GBM 肿瘤带来了独特的挑战。最近，免疫检查点抑制（ICI）形式的免疫疗法彻底改变了各种恶性肿瘤的治疗方法。免疫检查点抑制在 GBM 治疗中的应用显示出有前途的临床前结果。不幸的是，迄今为止，这在临床上几乎没有成功。在这篇综述中，我们将讨论 GBM 肿瘤带来的可能限制 ICI 效果的挑战，并讨论正在测试的克服这些挑战的方法。
相似文献
1
Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
Int J Mol Sci. 2020 Apr 16;21(8):2759. doi: 10.3390/ijms21082759.
2
Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Int Immunopharmacol. 2021 Apr;93:107403. doi: 10.1016/j.intimp.2021.107403. Epub 2021 Feb 12.
3
Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review).
Mol Med Rep. 2024 Dec;30(6). doi: 10.3892/mmr.2024.13344. Epub 2024 Oct 4.
4
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y.
5
Immune-Checkpoint Blockade Therapy in Lymphoma.
Int J Mol Sci. 2020 Jul 30;21(15):5456. doi: 10.3390/ijms21155456.
6
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Immunol Lett. 2020 Apr;220:88-96. doi: 10.1016/j.imlet.2019.03.006. Epub 2019 Mar 15.
7
Clinical Challenges of Immune Checkpoint Inhibitors.
Cancer Cell. 2020 Sep 14;38(3):326-333. doi: 10.1016/j.ccell.2020.07.004. Epub 2020 Aug 3.
8
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
JCI Insight. 2021 Sep 22;6(18):e142980. doi: 10.1172/jci.insight.142980.
9
New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors.
Curr Cancer Drug Targets. 2017;17(3):282-289. doi: 10.2174/1568009616666160813183738.
10
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002181.
引用本文的文献
1
Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications.
Front Immunol. 2025 Aug 25;16:1633338. doi: 10.3389/fimmu.2025.1633338. eCollection 2025.
2
Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions.
Cancer Innov. 2025 Jul 3;4(4):e70018. doi: 10.1002/cai2.70018. eCollection 2025 Aug.
3
Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function.
J Exp Clin Cancer Res. 2025 Jul 2;44(1):183. doi: 10.1186/s13046-025-03442-3.
4
Immune Checkpoint Inhibition Perturbs Neuro-immune Homeostasis and Impairs Cognitive Function.
Res Sq. 2025 Apr 25:rs.3.rs-6389488. doi: 10.21203/rs.3.rs-6389488/v1.
5
Tumor perfusion enhancement by focus ultrasound-induced blood-brain barrier opening to potentiate anti-PD-1 immunotherapy of glioma.
Transl Oncol. 2024 Nov;49:102115. doi: 10.1016/j.tranon.2024.102115. Epub 2024 Aug 31.
6
Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond.
Curr Issues Mol Biol. 2024 Jul 23;46(8):7795-7811. doi: 10.3390/cimb46080462.
7
Machine Learning-Directed Conversion of Glioblastoma Cells to Dendritic Cell-Like Antigen-Presenting Cells as Cancer Immunotherapy.
Cancer Immunol Res. 2024 Oct 1;12(10):1340-1360. doi: 10.1158/2326-6066.CIR-23-0721.
8
Safety and Efficacy of Laser Interstitial Thermal Therapy as Upfront Therapy in Primary Glioblastoma and IDH-Mutant Astrocytoma: A Meta-Analysis.
Cancers (Basel). 2024 Jun 3;16(11):2131. doi: 10.3390/cancers16112131.
9
Exosomes as drug delivery systems in glioma immunotherapy.
J Nanobiotechnology. 2024 Jun 18;22(1):340. doi: 10.1186/s12951-024-02611-4.
10
Therapeutic Targeting of Glioblastoma and the Interactions with Its Microenvironment.
Cancers (Basel). 2023 Dec 10;15(24):5790. doi: 10.3390/cancers15245790.
本文引用的文献
1
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
Neuro Oncol. 2020 Apr 15;22(4):539-549. doi: 10.1093/neuonc/noz185.
2
PD-L1/PD-1 Axis in Glioblastoma Multiforme.
Int J Mol Sci. 2019 Oct 28;20(21):5347. doi: 10.3390/ijms20215347.
3
Convection-Enhanced Delivery: Connection to and Impact of Interstitial Fluid Flow.
Front Oncol. 2019 Oct 2;9:966. doi: 10.3389/fonc.2019.00966. eCollection 2019.
4
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Cancer Immunol Res. 2019 Dec;7(12):1910-1927. doi: 10.1158/2326-6066.CIR-18-0865. Epub 2019 Oct 9.
5
Molecular and Clinical Insights into the Invasive Capacity of Glioblastoma Cells.
J Oncol. 2019 Jul 29;2019:1740763. doi: 10.1155/2019/1740763. eCollection 2019.
6
Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
BMC Cancer. 2019 May 30;19(1):519. doi: 10.1186/s12885-019-5741-y.
7
Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.
Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19.
8
The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion.
J Immunother Cancer. 2019 Feb 27;7(1):58. doi: 10.1186/s40425-019-0536-x.
9
Tumor targeting peptides: novel therapeutic strategies in glioblastoma.
Curr Opin Pharmacol. 2019 Aug;47:14-19. doi: 10.1016/j.coph.2019.01.006. Epub 2019 Feb 15.
10
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Neuro Oncol. 2019 Jun 10;21(6):730-741. doi: 10.1093/neuonc/noz015.
Zotero 插件